| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD8-HF255 | Human | FITC-Labeled Human CD38 Protein, Fc Tag |  |
|
|
| CD8-HF2H5 | Human | FITC-Labeled Human CD38 Protein, His Tag |  |
|
|
| MBC-K010 | Human | CD38-coupled magnetic beads | |||
| CD8-M5223 | Mouse | Mouse CD38 Protein, His Tag |  |
|
|
| CD8-C5223 | Cynomolgus | Cynomolgus CD38 Protein, His Tag |  |
|
|
| CD8-H5252 | Human | Human CD38 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| CD8-H5253 | Human | Human CD38 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| CD8-H5255 | Human | Human CD38 Protein, Fc Tag (MALS verified) |  |
|
|
| CD8-H82E7 | Human | Biotinylated Human CD38 Protein, Avitag™,His Tag |  |
|
|
| CD8-H5224 | Human | Human CD38 Protein, His Tag (MALS verified) |  |
|
|
Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | Approved | Janssen | DARZALEX FASPRO | fda | JANSSEN BIOTECH | 2020-05-01 | Multiple myeloma (MM) | Details | ||
| Daratumumab | JNJ-54767414 | Approved | Janssen | DARZALEX | fda | Multiple myeloma (MM) | JANSSEN BIOTECH | 2015-11-16 | Multiple myeloma (MM) | Details |
| Isatuximab | SAR-650984 | Approved | ImmunoGen, Sanofi | SARCLISA | fda | SANOFI AVENTIS US | 2020-03-02 | Multiple myeloma (MM) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| GBR-1342 | GBR-1342 | Phase Ⅰ | Glenmark Pharmaceuticals | Multiple myeloma (MM) | Details |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase Ⅰ | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple myeloma (MM) | Details | |
| TAK-079 | TAK-079 | Phase Ⅱ | Takeda | Multiple myeloma (MM) | Details |
| AMG-424 | AMG-424 | Phase Ⅰ | Xencor, Amgen | Multiple myeloma (MM) | Details |
| CART-38 | CART-38 | Phase Ⅱ | The First Affiliated Hospital of Soochow University | Acute myeloid Leukemia (AML) | Details |
| TAK-573 | TAK-573; TEV-48573 | Phase Ⅱ | Takeda | Multiple myeloma (MM) | Details |
| CID-103 | CID-103; TSK011010 | IND Filing | Tusk Therapeutics, CASI pharmaceuticals | hematological malignancies, Multiple myeloma (MM) | Details |
| TAK-169 | TAK-169 | Phase Ⅰ | Molecular Templates, Takeda | Multiple myeloma (MM) | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase Ⅱ | Shenzhen Geno-Immune Medical Institute | B-cell malignancies | Details |
| STI-6129 | STI-6129 | Phase Ⅰ | Sorrento Therapeutics | Amyloid light chain amyloidosis (AL amyloidosis) | Details |
| FT-500 | FT-500; FT-516; FT-538; FT-596 | Phase Ⅰ | Fate therapeutics, University of Minnesota | Solid tumours | Details |
| Y-150 | Y-150 | IND Filing | YZY Bio | Multiple myeloma (MM) | Details |
| 89Zr-DFO-daratumumab | Phase Ⅱ | Memorial Sloan Kettering Cancer Center | Contrast agents, Multiple myeloma (MM) | Details | |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | IND Filing | Hangzhou sumgen biotechnology | Unspecified | Details | |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | Phase Ⅰ | Sorrento Therapeutics, Celularity | Multiple myeloma (MM) | Details | |
| MOR-202 | MOR-202; MOR-03087; TJ-202 | Phase Ⅲ | MorphoSys, I-MAB Biopharma | Multiple myeloma (MM) | Details |
This web search service is supported by Google Inc.
A-Z